You sit down to finish an email. A notification pops up, you remember the laundry, and suddenly you have five tabs open, and the email still isn't done.
ADHD can make it hard to stay with a task, organize your next step, or pause before acting, even when you really want to. For many people with ADHD, the challenge isn't an inability to focus. It's regulating where attention goes.
Researchers are now exploring a new medication called ALKS 7290 that targets orexin, a brain chemical involved in wakefulness and attention. It's still experimental, but it could offer another approach to treating ADHD.
Think of Orexin as Part of Your Brain's "Stay Awake and Engaged" System
Imagine trying to work in a room where the lights keep dimming. You can still see your task, but staying engaged takes effort.
Activating orexin receptors is a little like adjusting those lights. Researchers want to find out whether it helps the brain maintain attention more consistently.
An important note: that's a comparison, not proof that ADHD comes from low orexin. The research is testing whether this pathway can help, rather than identifying one cause of ADHD. ADHD is complex, with many biological, psychological, and environmental contributors.
Wait, Isn't Orexin Connected to Sleep Medication?
Yes! Dayvigo (lemborexant), a prescription sleep medication, blocks orexin signals to help you sleep. ALKS 7290 does the opposite: it activates the orexin-2 receptor.
Think of the same lighting system: one medication turns the lights down for bedtime, while the experimental ADHD medication aims to turn them up for daytime engagement.
Is It Working?
Early results look promising. In a small, two-week study involving 50 adults with ADHD, people receiving ALKS 7290 improved on ADHD symptom ratings.
But improvement from the starting point doesn't automatically mean a medication beat placebo. This early study wasn't large enough to establish that difference.
Reported side effects included:
- Trouble sleeping
- Dizziness
- More frequent or urgent urination
- Constipation
What Does This Mean for Everyday Life?
The hope is that another treatment option could eventually help with things like finishing paperwork, following a conversation, or staying on track through a busy day. Those everyday benefits still need to be demonstrated.
The Bottom Line
A larger phase 2 trial is underway. As of October 2026, ALKS 7290 is not approved or available for routine prescribing. It's an interesting new direction to watch while researchers work out how well it helps, and who it helps most.
In the meantime, there are many effective, well-studied options for ADHD, including medication, therapy, coaching, and practical strategies built around how your brain works. If you're struggling with focus, organization, or follow-through, you don't have to wait for the next breakthrough to get support.
Questions about ADHD or your treatment options? NextGen Psyche and Wellness offers ADHD evaluations and treatment in English, Spanish, and Tagalog. Call us at 626-371-3053 to schedule an appointment.
This article is for educational purposes only and is not medical advice. Please talk with your healthcare provider before making any changes to your treatment.